[Report] GlaxoSmithKline Pharmaceutical Company Intelligenc TOC

Principal Operating Results
Latest Results

EXECUTIVE SUMMARY

Introduction
- Current Growth Drivers
- Key Late-Stage Products
Financial Performance 2005
- Sales and Market Position
- Income
  - Operating Income By Business Area
- Expenditure
  - Capital Expenditure
  - Capital Expenditure By Business Area
  - Capital Expenditure By Geographic Area
  - R&D Expenditure
  - Research & Development Expenditure By Business Area
- Divisional Performance
  - Sales By Business Area
  - Sales By Therapeutic Area
- Geographic Performance
  - Sales By Destination
  - Total Assets By Geographical Area
Company Strategy
- Mergers, Acquisitions and Divestitures
  - Acquisitions
  - Divestitures
- Key Agreements
- Production
- Employees
  - Employees By Geographical Area
  - Employees By Function
Product/R&D Overview
- Key Products
  - Recent Product Launches
  - Recent Product Approvals
- R&D Strategy
  - Key R&D Projects
- R&D Pipeline Overview
  - Discontinued R&D Projects
  - GI181771
  - 204937
  - GW810781 (S-1360)
  - Vilazodone (SB659746A)
  - GW320659 (1555U88)
  - GW328267
  - Hepatitis B vaccine
  - GW409544
  - Cantuzumab mertansine (SB408075)
  - Factive
  - GW650250A
  - GW876167 (BVT933)
  - GW660511 (Z13752A)
  - 202405
  - 221149
  - 423557
  - 423562
  - 493838
  - 656933
  - 766994
  - 825964
  - Allergy Vaccine
  - Goxalapladib
  - GW695634
  - GW873140
Conclusion/Outlook
- Sales Forecasts

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

Major Products, Therapeutic Areas And Sales
R&D Pipeline
Respiratory - Products
- Sales Of Major Respiratory Products
- Major Launched Products
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Generic Competition
  - Sales Forecast
- Flixotide/Flovent
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Delivery Systems - Diskus
  - Delivery Systems - Flovent Rotadisk
  - Delivery Systems - Others
  - Patents/Licensees
  - Competitor Products
  - Sales Forecast
- Seretide/Viani/Advair
  - Mode of Action
  - Sales
  - Key markets/Indications
  - Delivery Systems - Diskus Dry Powder Inhaler
  - Delivery Systems - Seretide Evohaler (MDI)
  - Delivery Systems - Other
  - Further Development
  - Patents/Licensees
  - Safety Issues
  - Competitor Products
  - Lawsuits
  - Sales Forecast
- Serevent
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Delivery Systems -Diskus/Accuhaler
  - Delivery Systems - Other
  - Patents/Licensees
  - Sales Forecast
Respiratory - R&D
- 159797 (TD-3327)
- 159802
- 233705
- 256066
- 597901
- 642444
- 656398
- 678007
- 681323
- 799943
- 856553
- 870086
- 961081
- Allermist/Avamys
  - Mode of Action
  - Development Status
- Ariflo
- Mepolizumab (SB240563)
Respiratory - Summary
- Growth Potential
- Limiting Factors
Neurosciences - Products
- Sales
- Sales Of Major CNS Disorder Products
- Major launched products
- Imigran/Imitrex
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - New Formulations
  - Patents/Lawsuits
  - Competitor Products
  - Generic Competition
  - Sales Forecast
  - Clinical Trial Results - Trexima
- Lamictal
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Patents/Licensees
  - Generic Competition/Lawsuits
  - Sales Forecast
- ReQuip/Adartel
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Patents/Licensees
  - Sales Forecast
  - Clinical Trial Results - Requip ER
- Seroxat/Paxil
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Paxil CR
  - Patents/Licensees
  - Safety Issues
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Wellbutrin
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Wellbutrin Once-Daily/Wellbutrin XL
  - Further Development
  - Patents/Licensees
  - Competitor Products
  - Lawsuits/Generic Competition
  - Sales Forecast
- Zyban
- Mode of Action
- Sales
- Key Markets/Indications
- Lawsuits/Generic Competition
- Sales Forecast
Neurosciences - R&D
- 163090
- 189254
- SB234551
- 274150
- 372475 (NS2359)
- GW406381
- 406725 (406724A)
- GW468816
- 644784
- SB683699 (T-0047)
- SB737004 (S-0139)
- 705498
- 742457
- 773812
- 823296
- 842166
- 876008
- AERx Pulmonary Drug Delivery System
- Casopitant
- Radafaxine
- Talnetant (SB223412)
- Vestipitant (GW597599)
Neurosciences - Summary
- Growth Potential
- Limiting Factors
Infectious Diseases - Products
- Sales Of Major Antiviral Products
- Sales Of Major Antibacterial Products
- Major launched products
- Agenerase
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Competitor Products
  - Sales Forecast
  - Clinical Trial Results
- Augmentin
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Generic Competition/Lawsuits
  - Sales Forecast
- Combivir
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Compassionate Use Programmes
  - Patents/Licensees
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Epivir
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Epzicom/Kivexa
  - Mode of Action
  - Key Markets/Indications
  - Clinical Trial Results
- Lapdap
  - Mode of Action
  - Key Markets/Indications
  - Further Development
  - Clinical Trial Results
- Relenza
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Diagnostic Tests
  - Patents/Lawsuits
  - Licensees
  - Sales Forecast
- Retrovir
  - Sales
  - Key Markets/Indications
  - Competitor Products
  - Generic Competition
  - Lawsuits
  - Sales Forecast
- Trizivir
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Competitor Products
  - Lawsuits
  - Sales Forecast
  - Clinical Trial Results
- Valtrex/Zelitrex
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Lawsuits
  - Sales Forecast
- Zeffix/Heptovir/Epivir-HBV
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Patents/Licensees
  - Sales Forecast
- Ziagen
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Zinnat/Ceftin
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Generic Competition/Lawsuits
  - Sales Forecast
- Zovirax
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Generic Competition
  - Sales Forecast
Infectious Diseases - R&D
- GR270773
- 565154
- 742510
- 825780
- Altabax
  - Clinical Trial Results
- Brecanavir
- Etaquine
- Farglitazar
- Sitamaquine
Infectious Diseases - Summary
- Growth Potential
- Limiting Factors
Cardiovascular - Products
- Sales Of Cardiovascular And Urogenital Products
- Major launched products
- Arixtra
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Clinical Trial Results
- Coreg
  - Mode of Action
  - Sales
  - Key MarketsIIndications
  - Competitor Products
  - Patents/Licensees
  - Generic Competition
  - Sales Forecast
  - Clinical Trial Results
Cardiovascular - R&D
- 256073
- GW501516
- 590735
- 681323
- 813893
- 856553
- Darapladib (480848; SB480848)
- Odiparcil
- Rilapladib
Cardiovascular- Summary
- Growth Potential
Urologenital - Products
- Major launched products
- Avolve/Avodart
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Sales Forecast
  - Clinical Trial Results
- Levitra
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Safety Issues
Urogenital - R&D
- 366074
- Casopitant
- Solabegron (GW427353)
Urogenital - Summary
- Growth Potential
- Limiting Factors
Musculoskeletal & Inflammation - R&D
- 232802
- 267268
- 270384
- 274150
- 681323
- SB683699 (T-0047)
- 751689
- 768974
- 842470
- 856553
- 876008
- Entereg
  - Mode of Action
  - Development Status
  - Clinical Trial Results - Opioid-induced Gastrointestinal
    - Side Effects
  - Clinical Trial Results - Post-Operative Ileus
- Mepolizumab (SB240563)
- Pazopanib (786034)
- Relacatib (462795; SB462795)
Musculoskeletal & Inflammation - Summary
- Growth Potential
- Limiting Factors
Metabolic - Products
- Sales Of Major Metabolic Products
- Avandia/Avandamet
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Avandamet (rosiglitazone+metformin)
  - Avandaryl
  - Further Development
  - Safety Issues
  - Licensees
  - Competitor Products
  - Patents/Lawsuits/Generic Competition
  - Sales Forecast
  - Clinical Trial Results - Diabetes Prevention
- Bondronat/Bonviva
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Clinical Trial Results
Metabolic - R&D
- 189075
- 625019
- GW677954
- 716155
- 869682
- 856464
- Radafaxine
- Redona
- Solabegron (GW427353)
Metabolic - Summary
- Growth Potential
- Limiting Factors
Gastrointestinal - Products
- Zantac
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Patents/Generic Competition
  - Sales Forecast
Gastrointestinal - Summary
Oncology - Products
- Sales Of Major Oncology Products
- Major launched products
- Atriance/Arranon
  - Mode of Action
  - Key Markets/Indications
  - Clinical Trial Results
- Hycamtin
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Patents/Licensees
  - Sales Forecast
- Zofran
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents/Licensees
  - Competitor Products
  - Generic Competition
  - Sales Forecast
Oncology - R&D
- 559448
- 743921
- Casopitant
- Elacridar
- Eltrombopag (SB-497115)
  - Clinical Trial Results
- Ethynylcytidine (SB596168)
- Iboctadekin (485232)
- Ispenesib (SB715992)
  - Clinical Trial Results
- Pazopanib (786034)
- Tykerb (lapatinib; GW570216)
  - Clinical Trial Results
- Vestipitant (GW597599)
Oncology - Summary
- Growth Potential
Vaccines - Products
- Sales Of Major Vaccines
- Major launched products
- Boostrix
  - Mode of Action
  - Key Markets/Indications
- Fluarix
- FluLaval/Fluviral
- Menitorix
- Paediatric Vaccines - Products
  - Infanrix/DTPa and Combinations
    - Sales
    - Key Markets/Indications
    - Combination Vaccines
    - Patents/Licensees
    - Sales Forecast
  - Priorix
  - Rotarix
    - Mode of Action
    - Key Markets/Indications
Vaccines - R&D
- Cervarix
  - Clinical Trial Results
- Dengue Fever Vaccine
- Epstein Barr Virus Vaccine
- Flu improved
- Flu Intranasal (FluINsure; FluNsure)
- Flu Pandemic
- Hepatitis E Vaccine (GLE438; GL438)
- Herpes Vvaccine
- HIV Vaccine
- Mosquirix Vaccine
  - Clinical Trial Results
- Simplirix
- Streptococcus Pneumoniae Vaccine
- Tuberculosis Vaccine
- Varicella Zoster Vaccine
- Paediatric Vaccines - R&D
  - Hib-MenCY-TT
  - Globorix
  - MenACWY-TT
  - Streptorix
- Pharmaccines - R&D
  - Breast Cancer Vaccine
    - Clinical Trial Results
  - Melanoma/Lung Cancer Vaccine
  - Prostate Cancer Vaccine
Vaccines - Summary
- Growth Potential

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2005

APPENDIX 2 - KEY AGREEMENTS

Adherex Technologies Inc
- 15th July 2005
- 28th September 2006
- 11th October 2006
Adolor Corporation
- 14th April 2002
- 3rd January 2005
Aeras Global TB Vaccine Foundation
- 20th October 2005
Antigenics Inc
- 10th July 2006
Aphton Corporation
- 19th June 1998
Asahi Chemical Industry Co
- 16th February 2000
Astellas Pharma
- 21st May 1998
- 7th June 2000
- 4th June 2003
- 8th August 2003
AVANT Immunotherapeutics Inc
- 19th October 1995
- 11th December 1997
- 9th March 2006
- 20th September 2006
Bavarian Nordic
- 15th July 2004
Bayer
- 1997
- 22nd July 1997
- 15th November 2001
- 18th February 2002
- 10th January 2005
bioMérieux-Pierre Fabre
- 10th January 2000
Bioseek Inc
- 6th July 2006
Biovail Corporation International
- 5th May 1998
- October 2001
- 27th December 2002
- 27th December 2002
Boehringer Ingelheim
- 13th March 1998
- 12th July 2004
Bristol-Myers Squibb
- May 1995
- 17th February 2000
- 9th August 2002
ChemoCentryx
- 24th August 2006
Crucell NV/Walter Reed Army Institute of
- Research
- 22nd October 2003
- 13th August 2004
Cytokinetics Inc
- 25th June 2001
- 13th December 2005
- 19th June 2006
Daiichi Sankyo
- 1993
- 15th July 1998
- 3rd December 2001
- 27th January 2003
Dainippon Sumitomo Pharma
- 28th December 2000
- 25th April 2002
Exelixis Inc
- 10th January 2005
- 9th May 2005
Galapagos nv
- 5th January 2005
- 7th June 2006
Genstruct Inc
- 8th August 2006
Human Genome Sciences Inc (HGS)
- May 1993
- 1995/1996
- June 1996
- 25th July 1997
- 16th October 2000
- 26th October 2004
- 7th July 2005
- 18th August 2005
- 10th January 2006
- diaDexus Agreement
- 16th October 2003
Institut Pasteur
- 17th December 2003
- 28th November 2005
Japan Tobacco (JT)
- 20th April 2006
Kissei Pharmaceutical
- 8th April 2006
Ludwig Institute for Cancer Research (LICR)
- 4th June 2006
MedImmune Inc/Aviron Inc
- 8th October 1995
- 10th December 1997
- 19th July 2000
- 29th August 2005
Merck & Co
- 14th April 1999
- 2nd February 2005
Millennium Pharmaceuticals Inc
- 23rd June 2004
Neurocrine Biosciences Inc
- 24th July 2001
NeuroSearch A/S
- 25th November 2002
- 19th December 2003
- November 2004
NiKem Research srl
- 10th June 2002
- 19th February 2003
- 1st August 2003
- 8th January 2004
Novo Nordisk
- 14th April 1998
Organon
- 7th January 2004
- 13th April 2004
Pharmacopeia Inc
- 30th March 2006
Pozen Inc
- 12th June 2003
- 16th July 2003
- 18th May 2004
Ranbaxy Laboratories Limited
- 11th March 1999
- 16th October 2001
- 22nd October 2003
Roche
- 1st February 1999
- 22nd December 2000
- 7th December 2001
- 19th July 2004
- 12th April 2005
Shionogi
- 19th October 2001
- 3rd March 2003
Sirna Therapeutics Inc
- 3rd April 2006
- 4th May 2006
SkyePharma PLC
- March 1996
- 13th September 1999
- 5th January 2004
- 28th April 2005
Taiho Pharmaceutical Company Ltd
- 25th July 2000
Tanabe
- 11th September 2001
- 18th June 2002
Teva Pharmaceutical Industries Ltd
- 1st July 2003
The International AIDS Vaccine Initiative (IAVI)
- 21st June 2005
The Malaria Vaccine Initiative (MVI) at Program for
- Appropriate Technology in Health (PATH)
- 1st March 2001
The Wellcome Trust / Institute of Cancer
- Research
- 27th July 2006
Theravance Inc
- 6th January 2003
- 11th May 2004
- 21st March 2005
Unigene Laboratories Inc
- 26th June 2003
University of California, San Francisco (UCSF)/
- Medicines for Malaria Venture (MMV)
- 11th October 2001
- 13th June 2003
Vertex Pharmaceuticals Inc
- Aurora Biosciences Agreement
- 10th January 2001
- 15th December 1999
- Vertex agreement
- December 1993
- 13th December 2005
Vitae Pharmaceuticals Inc
- 20th June 2005
- 13th July 2005
World Health Organization (WHO)
- 2nd March 2001
- 23rd April 2004

APPENDIX 3 - INFRASTRUCTURE

Research and Development Facilities
Manufacturing Facilities/Supply Chain
- Regional Manufacturing

APPENDIX 4 - KEY PHARMACEUTICAL

SUBSIDIARIES/JOINT VENTURES
Subsidiaries
Joint Ventures

APPENDIX 5 - PRODUCT INDEX

Index of Tables

Principal Operating Results
Operating Income By Business Area
Capital Expenditure By Business Area
Capital Expenditure By Geographic Area
Research & Development Expenditure By Business Area
Sales By Business Area
Sales By Therapeutic Area
Sales By Destination
Total Assets By Geographical Area
Employees By Geographical Area
Employees By Function
Recent Product Launches
Recent Product Approvals
Key R&D Projects
Major Products, Therapeutic Areas And Sales
R&D Pipeline
Sales Of Major Respiratory Products
Major Launched Products
Sales Of Major CNS Disorder Products
Major launched products
Sales Of Major Antiviral Products
Sales Of Major Antibacterial Products
Major launched products
Sales Of Cardiovascular And Urogenital Products
Major launched products
Major launched products
Sales Of Major Metabolic Products
Sales Of Major Oncology Products
Major launched products
Sales Of Major Vaccines
Major launched products

Index of Charts

Sales, Costs and Operating Income
Operating Income By Business Area, 2005
Capital Expenditure By Geographic Area, 2005
Capital Expenditure By Geographic Area, 2004
R&D Expenditure By Business Area
Sales By Business Area
Breakdown Of Sales By Therapeutic Area, 2005
Sales of Top 5 Therapeutic Areas
Sales By Destination, 2005
Total Assets By Geographical Area
Employees By Geographical Area, 2005
Employees By Function
Employees and Productivity
Sales Of Current Top 10 Products (2000A-2010E)
Top Selling Products, 2005
Sales Of Major Respiratory Products, 2005
Flixonase/Flonase Sales (2000A-2010E)
Flixotide/Flovent Sales (2000A-2010E)
Seretide Sales (2000A-2010E)
Serevent Sales (2000A-2010E)
Sales Of Major CNS Disorder Products, 2005
Imigran/Imitrex Sales (2000A-2010E)
Lamictal Sales (2000A-2010E)
ReQuip/Adartel Sales (2000A-2010E)
Seroxat/Paxil Sales (2000A-2010E)
Wellbutrin Sales (2000A-2010E)
Zyban Sales (2000A-2010E)
Sales Of Major Antiviral Products, 2005
Sales Of Major Antibacterial Products, 2005
Agenerase Sales (2000A-2010E)
Augmentin Sales (2000A-2010E)
Combivir Sales (2000A-2010E)
Epivir Sales (2000A-2010E)
Retrovir Sales (2000A-2010E)
Trizivir Sales (2000A-2010E)
Valtrex/Zelitrex Sales (2000A-2010E)
Zeffix Sales (2000A-2010E)
Ziagen Sales (2000A-2010E)
Zinnat Sales (2000A-2010E)
Zovirax Sales (2000A-2010E)
Sales Of Cardiovascular And Urogenital Products, 2005
Coreg Sales (2000A-2010E)
Avolve/Avodart Sales (2000A-2010E)
Sales Of Major Metabolic Products, 2005
Avandia/Avandamet Sales (2000A-2010E)
Zantac Sales (2000A-2010E)
Sales Of Major Oncology Products
Hycamtin Sales (2000A-2010E)
Zofran Sales (2000A-2010E)
Sales Of Major Vaccines, 2005
Infanrix Sales (2000A-2010E)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity

GlaxoSmithKline: Pipeline, Products, Performance, Potential

Table of Contents

EXECUTIVE SUMMARY

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

APPENDIX 1 - FINANCIAL PERFORMANCE

APPENDIX 2 - KEY AGREEMENTS

APPENDIX 3 - INFRASTRUCTURE

APPENDIX 4 - KEY PHARMACEUTICAL

APPENDIX 5 - PRODUCT INDEX

Index of Tables

Index of Charts